• Je něco špatně v tomto záznamu ?

COVID-19 and multiple sclerosis: challenges and lessons for patient care

L. Prosperini, G. Arrambide, EG. Celius, D. Goletti, J. Killestein, D. Kos, L. Lavorgna, C. Louapre, MP. Sormani, D. Stastna, T. Ziemssen, M. Di Filippo

. 2024 ; 44 (-) : 100979. [pub] 20240822

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002483

During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of disease-modifying treatments (DMTs). Key concerns arose, primarily related to the possibility that SARS-CoV-2 infection could trigger the initial demyelinating event or exacerbate disease activity. Another major concern was the safety and efficacy of the COVID-19 vaccines, especially for patients undergoing specific treatments that could weaken their antibody responses. In the post-infection phase, identifying long COVID in patients with MS has been complicated due to the large overlap between post-infection sequelae and MS symptoms. In addition, disruptions in health and rehabilitation services have made it difficult for MS patients to access care. This Series article explores current evidence on the interaction between MS and SARS-CoV-2, identifies the challenges posed by the COVID-19 pandemic in the care of patients with MS, and discusses the significant adoption of digital health solutions, including telemedicine and new technology-based rehabilitation approaches. Based on lessons learned, recommendations and future directions are offered for managing patients with MS, rethinking healthcare systems and improving health outcomes in the post-COVID-19 pandemic era.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002483
003      
CZ-PrNML
005      
20250123101919.0
007      
ta
008      
250117e20240822enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lanepe.2024.100979 $2 doi
035    __
$a (PubMed)39429966
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Prosperini, Luca $u MS Centre, Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy
245    10
$a COVID-19 and multiple sclerosis: challenges and lessons for patient care / $c L. Prosperini, G. Arrambide, EG. Celius, D. Goletti, J. Killestein, D. Kos, L. Lavorgna, C. Louapre, MP. Sormani, D. Stastna, T. Ziemssen, M. Di Filippo
520    9_
$a During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of disease-modifying treatments (DMTs). Key concerns arose, primarily related to the possibility that SARS-CoV-2 infection could trigger the initial demyelinating event or exacerbate disease activity. Another major concern was the safety and efficacy of the COVID-19 vaccines, especially for patients undergoing specific treatments that could weaken their antibody responses. In the post-infection phase, identifying long COVID in patients with MS has been complicated due to the large overlap between post-infection sequelae and MS symptoms. In addition, disruptions in health and rehabilitation services have made it difficult for MS patients to access care. This Series article explores current evidence on the interaction between MS and SARS-CoV-2, identifies the challenges posed by the COVID-19 pandemic in the care of patients with MS, and discusses the significant adoption of digital health solutions, including telemedicine and new technology-based rehabilitation approaches. Based on lessons learned, recommendations and future directions are offered for managing patients with MS, rethinking healthcare systems and improving health outcomes in the post-COVID-19 pandemic era.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Arrambide, Georgina $u Neurology-Neuroimmunology Department Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
700    1_
$a Celius, Elisabeth G $u Department of Neurology, Oslo University Hospital, Oslo, Norway $u Institute of Clinical Medicine, University of Oslo, Norway
700    1_
$a Goletti, Delia $u Translational Research Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy
700    1_
$a Killestein, Joep $u Department of Neurology, Amsterdam University Medical Centers, Amsterdam, the Netherlands
700    1_
$a Kos, Daphne $u National Multiple Sclerosis Center, Melsbroek, Belgium $u KU Leuven, Department of Rehabilitation Sciences, Leuven, Belgium
700    1_
$a Lavorgna, Luigi $u DAI Internal Medicine, Geriatric and Neurology, University Hospital "Luigi Vanvitelli", Naples, Italy
700    1_
$a Louapre, Celine $u Sorbonne Université, Paris Brain Institute-ICM, CIC Neurosciences, Hôpital de la Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, FCRIN4MS, Paris, France
700    1_
$a Sormani, Maria Pia $u Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy $u IRCCS Ospedale Policlinico San Martino, Genova, Italy
700    1_
$a Stastna, Dominika $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czechia
700    1_
$a Ziemssen, Tjalf $u Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
700    1_
$a Di Filippo, Massimiliano $u Section of Neurology, Department of Medicine and Surgery, University of Perugia, Italy
773    0_
$w MED00208007 $t The Lancet regional health. Europe $x 2666-7762 $g Roč. 44 (20240822), s. 100979
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39429966 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101913 $b ABA008
999    __
$a ok $b bmc $g 2254600 $s 1238486
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 44 $c - $d 100979 $e 20240822 $i 2666-7762 $m The Lancet regional health. Europe $n Lancet Reg Health Eur $x MED00208007
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Možnosti archivace